Precision Medical Sciences (Sep 2021)

Long noncoding RNA ZMIZ1‐AS1 promotes gefitinib resistance via binding to hnRNPA1

  • Changwen Jing,
  • Haixia Cao,
  • Jianzhong Wu,
  • Rong Ma,
  • Junying Zhang,
  • Siwen Liu,
  • Zhuo Wang

DOI
https://doi.org/10.1002/prm2.12051
Journal volume & issue
Vol. 10, no. 3
pp. 133 – 137

Abstract

Read online

Abstract To gain an insight into the molecular mechanisms of gefitinib resistance in nonsmall cell lung cancer, we screened out the long noncoding RNA related to gefitinib resistance through microarray data in gefitinib‐sensitive and resistant cells. lncRNA ZMIZ1‐AS1 was significantly upregulated in HCC827/GR cells by screening the microarray data. Further real‐time‐qPCR results were consistent with the microarray data. Cell viability assay and flow cytometry showed that ZMIZ1‐AS1 influenced the sensitivity of HCC827/GR cells to gefitinib. RNA pull‐down assay demonstrated that hnRNPA1 was a specific binding protein for ZMIZ1‐AS1. Our results help to reveal the role and mechanism of lncRNA in the secondary resistance of gefitinib and provide a new therapeutic target for gefitinib therapy.

Keywords